Arkolith/Insider Trading/PRLD/Form 4

Vaddi Krishna

CEO, DirectorPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Jan 2, 2025
Net Buying
Open-Market Buys
$12K
Open-Market Sells
$0
Net Open-Market Flow
$12K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 30, 2024Buy(P)10K$1.20$12K138K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML